Beta2-adrenergic ligand racemic formoterol exhibits enantioselective disposition in blood and skeletal muscle of humans, and elicits myocellular protein kinase A-signalling at therapeutic inhaled doses by Morton, H et al.
 This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/dta.2580 
 
This article is protected by copyright. All rights reserved. 
Hostrup Morten (Orcid ID: 0000-0002-6201-2483) 
Jacobson Glenn (Orcid ID: 0000-0002-3409-8769) 
Thevis Mario (Orcid ID: 0000-0002-1535-6451) 
 
Title Page 
Beta2-adrenergic ligand racemic formoterol exhibits enantioselective disposition in blood and 
skeletal muscle of humans, and elicits myocellular protein kinase A-signalling at therapeutic 
inhaled doses 
Running Title 
Enantioselective disposition of racemic formoterol in blood and muscle 
Morten Hostrup1*, Christian K. Narkowicz2, Sajad Habib1, David S. Nichols3, Glenn A. 
Jacobson2 
1Section of Integrative Physiology, Department of Nutrition, Exercise and Sports, University 
of Copenhagen, Copenhagen, 2Discipline of Pharmacy, School of Medicine, University of 
Tasmania, Hobart, Australia, 3Central Science Laboratory, University of Tasmania, Hobart, 
Australia 
Corresponding Author 
Morten Hostrup 
Section of Integrative Physiology 
Department of Nutrition, Exercise and Sports 
University of Copenhagen 
August Krogh Building 2nd floor 
Universitetsparken 13 
DK-2100 Copenhagen 
Denmark 
E-mail: mhostrup@nexs.ku.dk 
Tel: +45 2447 4785 
Fax: +45 3531 2179 
ORCID ID: 0000-0002-6201-2483  
  
This article is protected by copyright. All rights reserved. 
Abstract 
While studies have demonstrated substantial differences in beta2-adrenergic agonist 
enantiomer pharmacology, enantioselective disposition of long-acting beta2-adrenergic ligand 
racemic (rac)-formoterol in blood is unexplored after inhaled therapy given analytical 
challenges. Furthermore, information on enantioselective disposition and partitioning of beta2-
adrenergic agonist in skeletal muscle is absent despite its promising data on muscle anabolism 
in humans. Using a sensitive UPLC-MS/MS (ultra-high performance liquid chromatography-
mass spectrometry) assay, we determined disposition of (R,R)-formoterol and (S,S)-formoterol 
in plasma and skeletal muscle samples from 11 non-asthmatic men who had inhaled rac-
formoterol at therapeutic doses (2×27 µg). Mean (SD) concentrations of (R,R)- and (S,S)-
formoterol in plasma and in muscle biopsies of the vastus lateralis 1 h after inhalation of 
formoterol were 31 (15) and 45 (18) pg×mL-1 for (R,R)-formoterol and (S,S)-formoterol, 
respectively, in plasma, and 0.56 (0.32) and 0.51 (0.29) pg×mgwet wt
-1, respectively, in muscle. 
Formoterol exhibited different enantioselective disposition in plasma and muscle (p<0.0001). 
In plasma, mean log (R,R):(S,S)-formoterol ratio was lower than 0 [–0.17(0.07), p<0.0001], 
whereas in muscle, mean log (R,R):(S,S)-formoterol ratio was slightly higher than 0 
[0.04(0.07), p<0.05]. Log (R,R):(S,S)-formoterol ratio in muscle was related to muscle fibre-
type composition. Furthermore, formoterol induced an approximately two-fold increase in 
muscle p-PKASer/thr phosphorylation (p<0.01), indicating a substantial beta2-adrenergic 
response. Collectively, these findings suggest that formoterol exhibits modest enantioselective 
disposition in plasma after inhaled therapy in humans, which appear related to a greater (R,R)-
enantiomer disposition in skeletal muscle that may be dependent on fibre-type composition. 
Keywords: beta-adrenoceptor, beta2-adrenoceptor, beta-2, arformoterol, LABA 
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Introduction 
Inhaled beta2-adrenergic agonists (beta2-agonists) are commonly prescribed drugs, which is 
attributed to the high prevalence of asthma, exercise-induced bronchoconstriction and chronic 
obstructive pulmonary disease (COPD)1,2. While the primary application of inhaled beta2-
agonists is to induce bronchial smooth muscle relaxation, a large proportion of the drug enters 
the systemic circulation and distributes throughout the body3,4. Skeletal muscle, the largest 
tissue of the human body in non-obese individuals5, has a high density of beta-adrenoceptors 
of which the beta2-subtype accounts for approximately 90%
6,7. Stimulation of muscle beta2-
adrenoceptors with selective agonists modulates myocellular excitation-contraction coupling 
and metabolism8,9, which appear mediated by cAMP/protein kinase A (PKA)-dependent 
signalling10-12. Furthermore, beta2-agonists stimulate muscle protein turnover and growth
13-16. 
Given their anabolic and lipolytic properties, beta2-agonists have attracted interest as potential 
treatment in muscle wasting disorders and obesity17,18. 
 
Beta2-agonists are mainly sold as racemic (rac-) 1:1 mixtures, consisting of an R- and S-
enantiomer with different pharmacodynamics and pharmacokinetics3,19-21. It is generally 
accepted that the (R)-enantiomer is responsible for the pharmacological activity, whereas the 
(S)-enantiomer is generally considered pharmacodynamically inert22. The therapeutic 
application of beta2-agonists may therefore be superior for (R)-enantiopure formulations. There 
is a reasonable body of in vitro and in vivo work investigating enantioselective effects of beta2-
agonist R- and S-enantiomers in smooth muscle tissue of animals and humans mainly for 
respiratory research23, as well as interest as an anabolic and lipolytic agent17,18,24. However, 
despite a substantial body of literature on beta2-adrenergic effects in skeletal muscle
14,25, it is 
unexplored to what extent beta2-agonists distribute in skeletal muscle of humans and whether 
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any disposition is enantioselective. A handful of studies in animals have demonstrated 
enantioselective disposition of beta2-agonist clenbuterol
26-28 and salbutamol enantiomers in 
muscle tissue of rodents 29. Given the enantioselective disposition of beta2-agonists observed 
in blood and urine from humans3,20,21, it seems plausible that skeletal muscles are major 
enantioselective deposits for beta2-agonists.  
 
Formoterol, N-(2-hydroxy-5-((S)-1-hydroxy-2-(((S)-1-(4-methoxyphenyl)propan-2-yl)amino) 
ethyl) phenyl) formamide, is a long-acting beta2-agonist commonly prescribed in asthma as a 
rac- 1:1 mixture of (R,R)-formoterol and (S,S)-formoterol (Fig.1). There is little data on 
enantiomer levels of formoterol in humans, which may be related to analytic challenges 
associated with the microgram inhaled doses of formoterol administered clinically30. Median 
plasma concentrations of enantiomers following inhaled dosing with rac-formoterol were less 
than 15 pg×mL-1 following a 24 µg dose31 and there have been further studies reporting 
formoterol enantiomers in urine present at sub-nanogram concentrations20,32. Last, in spite of 
the promising data on formoterol in relation to energy expenditure17,33 and muscle protein 
turnover observed in clinical trials13, no study has determined enantiomer disposition and 
partitioning of formoterol in human skeletal muscle as well as the resultant canonical beta2-
adrenergic PKA-signalling response. 
 
The purpose of the present study was to determine enantioselective disposition of (R,R)- and 
(S,S)-formoterol in plasma and skeletal muscle of non-asthmatic men after inhaled therapy 
using UPLC-MS/MS (ultra-high performance liquid chromatography-mass spectrometry). 
Secondary purposes were to examine the muscle:plasma partition coefficient of each individual 
enantiomer, the relation between enantioselective disposition in muscle and muscle fibre-type 
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composition, and the beta2-adrenergic PKA-signalling response to rac-formoterol in human 
skeletal muscle. 
 
Materials and methods 
Volunteer study 
Stored venous plasma and vastus lateralis muscle biopsies sampled from 11 recreationally 
active men during a previous study34 were used for the present study. Subjects were 21–43 
years, 167–185 cm height and had a tissue mass of 72–103 kg (17–31% body fat). Subjects had 
no history of asthma and were beta2-agonist naive. Subjects were informed about potential risks 
and discomforts related to the study, and each subject gave written and oral informed consent 
prior to inclusion. The study was approved by the Committee on Health Research Ethics of the 
Capital Region of Denmark and performed in accordance with the Helsinki declaration.  
 
Sample collection 
The experimental protocol has been described in Kalsen et al. (2016)34. Briefly, subjects met 
in morning after an overnight fast and inhaled two doses of 27 µg formoterol (Oxis 
Turbohaler®, AstraZeneca, Cambridge, UK), with the two doses being separated by 45 min. 
Approximately 1 h after the second dose, a venous blood sample (4 mL) and a muscle biopsy 
were collected for determination of enantioselective disposition of rac-formoterol. The blood 
sample was drawn in a gel-free lithium heparin tube (BD vacutainer, NJ, US) from a catheter 
in the medial ante cubital vein and stood in room temperature for 15 min before being spun at 
4000 rpm for 15 min after which plasma was collected and stored at –80 °C until analysis. 
Muscle biopsies were sampled from the vastus lateralis using a 4-mm Bergström needle with 
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suction35. Prior to sampling, an incision was made through the skin and fascia at the belly of 
the vastus lateralis muscle during local anesthesia with lidocaine (2 mL lidocaine without 
epinephrine, Xylocaine® 20 mg×mL-1, AstraZeneca, Cambridge, UK). Muscle biopsy 
specimens were snap-frozen in liquid nitrogen and stored at –80 °C until analysis.  
 
Analysis of (R,R)- and (S,S)-formoterol enantiomer levels in plasma and muscle 
Plasma and muscle biopsy samples were couriered from University of Copenhagen, Denmark 
to University of Tasmania, Australia under dry ice temperature-controlled conditions, where 
the chemical analyses were undertaken.  
 
Enantioselective formoterol analyses follow on from our previous beta2-agonist work
29,36 with 
the assay optimised for formoterol.  Analyses were  undertaken using UPLC-MS/MS (ultra-
high performance liquid chromatography-mass spectrometry) consisting of a Waters Acquity® 
H-class UPLC system coupled to a Waters Xevo® triple quadrupole mass spectrometer; Waters 
Corporation, Milford, MA) with chromatography performed using an Astec® 
CHIROBIOTIC™ T2 chiral column (4.6×250 mm×5 μm particles) (Sigma-Aldrich, St. Louis, 
MI, US).  
 
Pieces of muscle tissue (20 to 200 mgwet wt) were weighed with an electron scale. Water 
(deionised, 500 μL), ammonia solution (pH ~10, 3.2 μL×mg-1 tissue mass) and 10 μL internal 
standard solution (rac-formoterol-D6; Toronto Research Chemicals, Toronto, Canada) 
equivalent to 10 ng were added. The muscle tissue was homogenised in this mixture using a 
mechanical rotor type tissue homogeniser (Tissue-Tearor, Biospec Products USA) until no 
intact muscle tissue was evident. Homogenate was adjusted to a pH of 8.5. Ethyl acetate (1 
mL) was added to the homogenate and mixed using the homogeniser for 1 min. The tube was 
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then centrifuged at 15,000 g for 15 min. The separated ethyl acetate fraction was transferred 
into a glass vial. The tissue homogenate was extracted a second time with ethyl acetate in a 
similar fashion and the ethyl acetate fraction was combined with the first extract. Samples for 
analysis were prepared from this extract as described below.  
 
Calibration samples were prepared by spiking drug free human plasma and bovine skeletal 
muscle samples with unlabelled rac-formoterol (formoterol fumarate dihydrate; Carbosynth, 
Compton, UK) over the calibration ranges of 0-20 and 0-10 ng×mL-1 for plasma and muscle, 
respectively. Internal standard (rac-formoterol-D6; Toronto Research Chemicals, Toronto, 
Canada) equivalent to 10 ng was added to each calibration and study sample aliquot (400 μL), 
then dilute ammonia solution (150 μL) was added to each and vortex mixed before the addition 
of 850 μL of HPLC grade ethyl acetate. This was vortex mixed for one min and then centrifuged 
at 15,000 g for five min. The organic supernatant was then collected, and the ethyl acetate 
extraction repeated and the two residues combined; solvent was then evaporated under nitrogen 
at 40 °C and reconstituted using 80 μL of methanol and vortex mixed prior to analysis via 
UPLC-MS/MS.  
  
Analyses were undertaken using multiple reaction monitoring (MRM) in positive electrospray 
ionisation mode. The UPLC was operated with a mobile phase consisting of 100% methanol 
with 0.2% acetic acid and 0.025% ammonium hydroxide.  Elution was isocratic for 30 min.  
The flow rate was 0.8 mL×min-1 and the column was held at room temperature. Injection 
volume was 50 μL. Electrospray ionisation was performed with a capillary voltage of 2.76 KV, 
a cone voltage of 30 V and individual collision energies for each MRM transition, as described 
below. The desolvation temperature was 450 °C, nebulising gas was nitrogen at 950 L×h-1 and 
cone gas was nitrogen at 50 L×h-1. MRM transition monitored for formoterol was (m/z) 345 to 
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149,  (collision energy 19 V),  and MRM transition monitored for formoterol-D6 was (m/z) 351 
to 155,  (collision energy 19 V). Dwell time per channel was 36 ms.  
 
Confirmation of enantiomer elution order was undertaken by analysis of (R,R)-formoterol 
standard (TLC Pharmaceutical Standards, Ontario, Canada). The “drop perpendicular” method 
of peak integration was used where a vertical line from the valley of the peaks is dropped to 
the horizontal baseline. The method detection limit (MDL) was determined by signal-to-noise 
ratio (S/N=3) extrapolated from the 0.2 ng×mL-1 calibration standard, accuracy (n=4) was 
estimated at the 1 and 2 ng×mL-1 for plasma and muscle, respectively, and precision estimated 
across the calibration range (0.2-20 and 0.1-10 ng×mL-1 for plasma and muscle, respectively; 
each n=4).  For muscle:plasma partition coefficient (Km) determinations, ng×mL
-1 (plasma) 
was considered equivalent to ng×g-1 (muscle). 
 
Immunoblotting and SDS-page 
Western blotting was performed as previously described25. In brief, muscle pieces were 
homogenized (Qiagen Tissuelyser II, Retsch GmbH, Haan, Germany) in a fresh batch of buffer 
(10% glycerol, 20 mM Na-pyrophosphate, 150 mM NaCl, 50 mM HEPES (pH 7.5), 1% NP-
40, 20 mM β-glycerophosphate, 2 mM Na3VO4, 10 mM NaF, 2 mM PMSF, 1 mM EDTA (pH 
8), 1 mM EGTA (pH 8), 10 µg×mL-1 Aprotinin, 10 µg×mL-1 Leupeptin and 3 mM 
Benzamidine). Samples were rotated end over end for 1 h at 4 °C and centrifuged at 18,320 g 
for 20 min at 4 °C to exclude non-dissolved structures and the supernatant (lysate) was used 
for further analyses. Total protein concentration in each sample was determined by a BSA 
standard kit (Thermo Fisher Scientific, Hvidovre, Denmark) and samples were mixed with 
6×Laemmli buffer (7 mL 0.5 M Tris-base, 3 mL glycerol, 0.93 g DTT, 1 g SDS and 1.2 mg 
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bromophenol blue) and ddH2O to achieve equal protein concentration. Equal amount of protein 
was loaded in each well of pre-casted gels (Bio-Rad Laboratories, US). Samples from same 
subject were loaded next to each other on the same gel with a mixed human muscle standard 
lysate loaded in two different wells used for normalization. Proteins were separated according 
to their molecular weight by SDS page gel electrophoresis and semi-dry transferred to a PVDF 
membrane (Bio-Rad Laboratories, US). The membranes were blocked in either 2% skimmed 
milk or 3% BSA in Tris-buffered Saline including 0.1% Tween-20 (TBST) before an overnight 
incubation in primary antibody at 4 °C and a subsequent 1 h incubation in horseradish-
peroxidase (HRP) conjugated secondary antibody at room temperature. The bands were 
visualised with ECL (Millipore) and recorded with a digital camera (ChemiDoc MP Imaging 
System, Bio-Rad Laboratories, US). Densitometry quantification of the western blot band 
intensity was performed using Image Lab version 4.0 (Bio-Rad Laboratories, US) and 
determined as the total band intensity adjusted for background intensity. The primary 
antibodies used were phospho-(Ser/Thr) PKA substrate (#9621, Cell signalling, MA, US), 
SERCAI (MA3-912, Thermo Fischer Scientific, MA, US) and SERCAII (SC-8095, Santa Cruz 
Biotechnology, TX, US). Secondary antibodies used were HRP conjugated rabbit anti-sheep 
(P-0163, DAKO, Glostrup, Denmark), goat anti-mouse (P-0447, DAKO, Glostrup, Denmark) 
and goat anti-rabbit IgM/IgG (4010-05 Southern Biotech, AL, US).  
 
Myosin heavy chain composition in muscle homogenate 
Myosin heavy chain (MHC) composition of the vastus lateralis muscle was determined from 
homogenate using gel electrophoresis as described previously37. Muscle homogenate prepared 
as described for Western blotting was diluted with 6×Laemmli sample-buffer (7 mL 0.5 M 
Tris-base, 3 mL glycerol, 0.93 g DTT, 1 g SDS and 1.2 mg bromophenol blue) and 100% 
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glycerol (50/50). A total of 1 µg of protein was separated on 8% self-cast stain free gels (49:1 
acrylmid : bis-acrylmid, 30% glycerol, 200 mM Tris-base, 0.4% SDS, 0.1% APS and 0.1 M 
glycine) containing 0.5% 2,2,2 Trichloroethanol38 for 16 h at 140 V on ice. MHC protein bands 
were visualized by ultraviolet activation of the stain free gel (ChemiDoc MP Imaging System) 
and were quantified densitometrically using imaging software (Image Lab v. 4.0, Bio-Rad 
Laboratories, Hercules, CA, US). 
 
Statistics 
Statistical analyses were performed in SPSS version 25 (IBM, Armonk, NY, US). Data were 
tested for normality using the Shapiro-Wilks test and Q-Q plots. Variables that violated 
normality were log-transformed. To estimate enantioselective disposition in plasma and 
muscle, one-sample t-test was used. To estimate tissue differences in enantioselective 
disposition between plasma and muscle, two-tailed linear mixed modelling was used with 
tissue as a fixed effect. To estimate association between subjects’ muscle fibre type 
composition and muscle enantioselective disposition of formoterol, principal component 
analysis (PCA) with varimax rotation and multiple linear regression analysis were used. A 
comparison of muscle:plasma partitioning between enantiomers was assessed by paired 
student’s t-test. Data are presented as mean and standard deviations (SD), unless otherwise 
stated, and exact p-values (unless lower than 0.001) to represent probability.  
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Results 
Enantioselective UPLC-MS/MS assay performance 
All matrices met acceptance criteria for accuracy (<15% deviation), precision (<15%RSD), 
recovery >20% in plasma and muscle, and estimate of linearity (r2>0.999).  For plasma, the 
MDL was 7 pg×mL-1 for both (R,R)- and (S,S)-formoterol. The MDL in muscle was variable 
and determined by biopsy mass; therefore based on a mean biopsy wet mass of 83 mg, MDL 
was estimated to be equivalent to 0.09 pg×mg-1 (but would be lower for larger biopsy mass and 
vice versa). All tissue samples had measurable levels of formoterol enantiomers with signal to 
noise ratio >10. Precision (%RSD) for plasma (R,R)- and (S,S)-formoterol was 12.2 and 8.9%, 
respectively; precison for muscle (R,R)- and (S,S)-formoterol was 11.6 and 10.9%, 
respectively. Accuracy deviation (%) for plasma (R,R)- and (S,S)-formoterol was 5.0 and 1.8%, 
respectively; accuracy deviation for muscle (R,R)- and (S,S)-formoterol was 3.2 and 4.9%, 
respectively.  Example chromatograms of a muscle and plasma sample are shown in Figure 2. 
 
(R,R)- and (S,S)-formoterol enantiomer disposition in plasma and skeletal muscle  
Enantiomer levels of (R,R)- and (S,S)-formoterol in plasma and in muscle biopsies of the vastus 
lateralis 1 h after inhalation of formoterol are presented in figure 3. Mean(SD) plasma 
concentrations were 31(15) and 45(18) pg×mL-1 for (R,R)-formoterol and (S,S)-formoterol, 
respectively, and mean(SD) muscle concentrations were 0.56(0.32) and 0.51(0.29) pg×mgwet 
wt
-1 for (R,R)-formoterol and (S,S)-formoterol, respectively (Fig. 3A-B). Formoterol exhibited 
different enantioselective disposition in plasma and muscle (p < 0.0001)(Fig. 3C). In plasma, 
mean log (R,R):(S,S)-formoterol ratio was lower than 0 [–0.17(0.07), p < 0.0001], whereas in 
muscle, mean log (R,R):(S,S)-formoterol ratio was slightly higher than 0 [0.04(0.07), p = 0.046] 
(Fig. 3C). The mean(SD) muscle:plasma partition coefficient (Km) was 14.3(6.7) for rac-
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formoterol, 18.9(9.7) for (R,R)-formoterol and 11.4(5.0) for (S,S)-formoterol indicating 
partitioning of both enantiomers into muscle with (R,R)-formoterol partitioning to a greater 
extent than (S,S)-formoterol (p = 0.0012).  
 
Muscle fibre-type composition and enantioselective disposition 
Principal component analysis revealed that muscle (R,R):(S,S)-formoterol ratio loaded together 
with muscle SERCAI content and MHCII distribution on the first principal component (Fig. 
4A). There was a significant correlation [r2adj = 0.56, p = 0.015] between muscle log(R,R):(S,S)-
formoterol ratio and principal component scores of muscle SERCAI+II content and MHCI+II 
distribution in a multiple linear regression (fig. 4B). 
 
Muscle PKA-signalling 
Inhalation of formoterol induced significant PKA-signalling in human vastus lateralis muscle 
1 h after administration as indicated by an approximately two-fold greater p-PKASer/thr 
phosphorylation for formoterol than placebo-control (p = 0.002)(Fig. 5).  
 
Discussion 
Herein we have described the enantioselective disposition of (R,R)- and (S,S)-formoterol in 
plasma and skeletal muscle in non-asthmatic men who inhaled repetitive therapeutic doses of 
rac-formoterol (2×27 µg). In addition, we investigated the PKA-signalling response to 
formoterol in human skeletal muscle. The new findings of the study are 1) that formoterol 
exhibits modest, but divergent enantioselective disposition in plasma and muscle after inhaled 
administration, 2) that formoterol partitions into muscle with (R,R)-formoterol partitioning to 
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a greater extent than (S,S)-formoterol, 3) that the enantioselective disposition in muscle is 
associated with muscle fibre-type composition, and 4) that inhalation of formoterol in 
therapeutic doses elicits a significant beta2-adrenergic PKA-signalling response in skeletal 
muscle. 
 
To the best of our knowledge, the present study is first to investigate formoterol enantiomer 
levels in skeletal muscle of humans following inhalation therapy. In the past, determination of 
individual formoterol enantiomers in biological fluids has been limited by assay performance 
in studies that employed HPLC30. We successfully developed a sensitive and specific UPLC-
MS/MS assay with a MDL of around 7 pg×mL-1, equivalent to around 3 pg on column, 
sufficient to measure formoterol enantiomers in human plasma and muscle tissue. Accordingly, 
all plasma and muscle samples collected in the present study had measurable levels of each 
formoterol enantiomer. In our laboratory, we have found formoterol enantiomers are more 
difficult to measure than other beta2-agonists, as there is a more significant trade-off between 
mobile phase composition for sensitivity and selectivity compared to for example salbutamol 
enantiomers. 
 
We observed that rac-formoterol exhibited a modest enantioselective disposition in plasma and 
muscle with relatively lower (R,R)-formoterol than (S,S)-formoterol in plasma and higher 
(R,R)-formoterol than (S,S)-formoterol disposition in muscle 1 h after repetitive inhalation of 
rac-formoterol. Other beta2-agonists, such as rac-salbutamol, have been shown to exhibit 
extensive enantioselective disposition in the circulation, where the plasma S-enantiomer 
resides in higher concentrations than the active R-enantiomer. This is consistently observed in 
a number of salbutamol pharmacokinetic parameters3,39. Although the degree of 
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enantioselective disposition in plasma is much lower for rac-formoterol than that observed for 
salbutamol, every subject had higher plasma concentrations of the (S,S)-enantiomer than the 
(R,R)-enantiomer in the present study.  
 
The higher concentration of (S,S)-formoterol in plasma may be related to several factors. 
Firstly, the present study indicates that skeletal muscle exhibits some degree of enantioselective 
partitioning in favour of the (R,R)-enantiomer. Although the degree of enantioselective 
disposition in muscle was small, skeletal muscle encompasses approximately 40% of body 
mass in non-obese individuals5, meaning that even a minor difference between enantiomers in 
muscle could have a large effect on circulating levels of (R,R)- and (S,S)-formoterol. Secondly, 
studies have demonstrated enantioselective differences in the urine excretion of unchanged 
formoterol. Oral and inhaled administration of rac-formoterol has been reported to result in 
higher levels of unchanged (S,S)-formoterol in urine20,40. Last, enantioselective metabolism of 
formoterol via the glucuronidation pathway may be a factor, as total levels of (R,R)-formoterol 
(unchanged drug and glucuronide metabolite) has been shown to predominate in urine, at least 
following oral dosing40.  
 
Our observation of a slightly higher disposition of the (R,R)-enantiomer of formoterol in 
skeletal muscle is consistent with the enantioselective disposition observed for salbutamol in 
rodents29. However, in contrast to the modest degree for formoterol, salbutamol exhibits more 
extensive enantioselective disposition in rat skeletal muscle, where the R-enantiomer of 
salbutamol resides in much higher concentrations than the S-enantiomer. Collectively, these 
observations suggest that distribution kinetics of beta2-agonists are enantioselective with a 
preference of the R-enantiomers in muscle tissue and S-enantiomers in the circulation. It should 
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also be noted that compared to rac-salbutamol, the muscle:plasma partition coefficient (Km) 
for rac-formoterol in the present study was greater than that previously reported in a rodent 
model for oral dosing of salbutamol (14.3 versus 3.8)29, acknowledging that the route of 
administration (oral) and sampling (4 h) were also different. This greater partitioning could be 
a pharmacokinetic factor for consideration of formoterol as a preferential therapeutic for 
muscle wasting and obesity13,17,33 or doping misuse34 compared to the short acting salbutamol. 
 
While animal models have indicated that slow-twitch dominated muscles (e.g. soleus) respond 
differently to beta2-agonists than fast-twitch dominated (e.g. extensor digitorum longus)
18, it is 
unknown whether muscle fibre-type specific differences exist in the disposition of beta2-
agonist enantiomers. Given human skeletal muscle predominantly has a mixed fibre-type 
composition as compared to rodents, we performed an exploratory analysis of the association 
between muscle fibre-type composition and enantioselective disposition of (R,R)- and (S,S)-
formoterol in muscle. Muscle fibres can be classified according to MHC isoform distribution 
and SERCA isoforms41,42, in which slow-twitch fibres predominantly express MHCI and 
SERCAII, whereas fast-twitch fibres express MHCII and SERCAI. We observed that muscle 
(R,R):(S,S)-formoterol ratio loaded together with MHCII and SERCAI in a principal 
components analysis. This suggests that the enantioselective disposition of (R,R):(S,S)-
formoterol may be fibre type-specific in humans, with a higher relative disposition of (R,R)-
formoterol in fast-twitch fibres as compared to slow-twitch fibres.  
 
The main canonical signalling pathway associated with the beta2-adrenoceptor is the 
cAMP/PKA-dependent11,12. The repetitive inhaled therapeutic dose of formoterol administered 
in the present study was sufficient to induce significant beta2-adrenergic cAMP/PKA signalling 
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in skeletal muscle 1 h after inhalation. As such, formoterol induced a two-fold greater 
PKASer/Thr phosphorylation in the vastus lateralis muscle. This observation underpins the 
efficacy of formoterol in activating beta2-adrenergic signalling pathways in skeletal muscle, 
even after inhalation in therapeutic doses. The formoterol-induced PKA-signalling in skeletal 
muscle likely explains the apparent effects of formoterol on protein turnover and substrate 
utilization observed in previous studies13,17,33,34. 
 
An important consideration of the present study was that muscle concentrations of formoterol 
enantiomers were determined 1 h after inhalation of two repetitive doses of rac-formoterol, 
consistent with time to reach maximum plasma levels (tmax)
20. Given the observation that the 
pharmacokinetics of individual formoterol enantiomers in plasma differ20,31, it is likely that 
(R,R)- and (S,S)-formoterol concentrations also exhibit a different time-course in muscle. For 
instance, it may be that (R,R)- and (S,S)-formoterol have differential partitioning, distribution 
and clearance kinetics in skeletal muscle. Such assessment, however, would require repeated 
muscle biopsy sampling for several hours because of the relatively long half-life of 
formoterol20,31. In addition, substantial inter-variability exists in the pharmacokinetics of beta2-
agonists, which is also reflected by the spread of the formoterol enantiomer concentrations 
observed in plasma and muscle in the present study. 
In summary, the present study shows that rac-formoterol exhibits modest, but significant and 
divergent enantioselective disposition in the circulation and skeletal muscle of humans. Despite 
the therapeutic inhaled dose used, formoterol partitioned in muscle to an extent that was 
sufficient to induce a significant PKA-signaling response. Furthermore, our data indicate that 
the disposition of the (R,R)-enantiomer in human skeletal muscle may be fiber-type specific. 
The application of beta2-agonists in treatment of muscle wasting and for weight-loss has been 
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suggested by several authors17,18, and formoterol has been shown to effectively increase energy 
expenditure and to induce protein anabolism in clinical trials13,17. Given that the activity of 
formoterol resides with the (R,R)-enantiomer, being 1,000 times more potent than the (S,S)-
enantiomer19, our observations of greater partitioning of (R,R)-formoterol in muscle provide a 
rationale for chiral switch enantiopure (R,R)-formoterol rather than racemic mixture in future 
clinical trials for the purpose of increasing muscle metabolic rate and anabolism. For doping 
control purposes relating to beta2-agonists, it may also be that more emphasis should be on 
analysis of the R-enantiomers. Indeed, a significant number of enantiopure beta2-agonist 
products are available on the market. 
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Fig. 1. Molecular structure of (R,R)-formoterol (upper panel) and (S,S)-formoterol (lower 
panel). 
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Fig. 2. Example chromatogram from a subject showing low level formoterol enantiomers in a 
muscle sample extract equivalent to 0.18 and 0.12 pg×mg-1 biopsy wet weight for (R,R)-
formoterol and (S,S)-formoterol, respectively (A), and a corresponding plasma sample (B). 
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Fig. 3. Concentrations of (R,R)-formoterol and (S,S)-formoterol in plasma (A) and human 
vastus lateralis muscle (B), and enantioselective disposition [log(R,R):(S,S)-formoterol] in 
plasma and muscle (C). Individual values (n=11). 
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Fig. 4. Principal component analysis (A) and multiple linear regression analysis (B). 
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Fig. 5. Left panel shows individual values for p-PKASer/thr in human vastus lateralis muscle in 
subjects (n=11) who inhaled either placebo or formoterol (2×27 µg). Right panel shows 
representative blots for three subjects (C: placebo sample, F: formoterol sample). 
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Graphical Abstract 
Information on enantioselective disposition and partitioning of beta2-adrenergic agonists in 
skeletal muscle is absent despite their apparent clinical effects in human muscle. Herein we 
show that rac-formoterol exhibits modest, but significant and divergent enantioselective 
disposition in the circulation and skeletal muscle of humans. Despite the therapeutic inhaled 
dose used, formoterol partitioned in muscle to an extent that was sufficient to induce a 
significant PKA-signaling response. 
 
 
 
